AndrewBLassmanMD, MS, FAAN

Neurooncology

Neuro-Oncology Division Chief, Associate Dean of Clinical Trials

Overview of Dr. Lassman

Dr. Andrew Lassman is a neurologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and Valley Hospital. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 24 years. Dr. Lassman accepts several types of health insurance, listed below. He is one of 473 doctors at New York-Presbyterian Hospital and one of 209 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Neurology. He has more than 100 publications and over 500 citings.

Office
710 West 168th Street
New York, NY 10032
Book by Phone+1(301) 744-8991
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Neuro-Oncology, 2001 - 2003
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 1998 - 2001
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalInternship, Internal Medicine, 1997 - 1998
Columbia University Vagelos College of Physicians and SurgeonsClass of 1997, MD

Certifications & Licensure

NJ State Medical License 2022 - 2025
NY State Medical License 1998 - 2025
CT State Medical License 2023 - 2024
KS State Medical License 2021 - 2024
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly
America's Top Doctors Castle Connolly
Top Doctors: New York Metro Area Castle Connolly
America's Top Doctors for Cancer Castle Connolly
Join now to see all

Clinical Trials

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Start of enrollment: 2007 Jan 24
Completed
Phase 2
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Start of enrollment: 2007 Jun 01
Completed
Phase 2
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Start of enrollment: 2007 Oct 01
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Start of enrollment: 2007 Oct 01
Completed
Phase 2
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas Start of enrollment: 2011 Jan 07
Completed
Phase 1
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2013 Jul 18
Completed
Phase 1, Phase 2
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma Start of enrollment: 2014 Jan 09
Terminated
Phase 1, Phase 2
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy Start of enrollment: 2013 Nov 27
Completed
Phase 2
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM Start of enrollment: 2013 Dec 09
Completed
Phase 2
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas Start of enrollment: 2014 Mar 03
Terminated
Phase 2
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Start of enrollment: 2014 Dec 08
Completed
Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects Start of enrollment: 2017 Dec 06
Recruiting
Phase 1, Phase 2
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Start of enrollment: 2020 Sep 01
Active, not recruiting
Phase 2, Phase 3
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2020 Jun 08
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

7 citations
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Patrick Y Wen, Martin van den Bent, Gilbert Youssef, Timothy F Cloughesy, Benjamin M Ellingson, Michael Weller, Evanthia Galanis, Daniel P Barboriak, John de Groot, Ma...> ;Journal of Clinical Oncology. 2023 Nov 20
15 citations
Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.
Maximilian J Mair, Rupert Bartsch, Emilie Le Rhun, Anna S Berghoff, Priscilla K Brastianos, Javier Cortes, Hui K Gan, Nancy U Lin, Andrew B Lassman, Patrick Y Wen, Mic...> ;Nature Reviews. Clinical Oncology. 2023 Jun 1
4 citations
What is a glioblastoma?
Andrew B Lassman, Martin J van den Bent> ;Neuro-Oncology. 2023 Jun 2
10 citations
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Benjamin M Ellingson, Patrick Y Wen, Susan M Chang, Martin van den Bent, Michael A Vogelbaum, Gang Li, Shanpeng Li, Jiyoon Kim, Gilbert Youssef, Wolfgang Wick, Andrew ...> ;Neuro-Oncology. 2023 Jun 2
3 citations
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced gliob...
Benedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, Andrew B Lassman, Saiama N Waqar, Young Kwang Chae, Jyoti D Patel, Einat Shacham-Shmueli, Karen Kelly, ...> ;Neuro-Oncology Advances. 2022 Dec 21
14 citations
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial.
Eleonora F Spinazzi, Michael G Argenziano, Pavan S Upadhyayula, Matei A Banu, Justin A Neira, Dominique M O Higgins, Peter B Wu, Brianna Pereira, Aayushi Mahajan, Nels...> ;The Lancet. Oncology. 2022 Nov 1
14 citations
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.
Andrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, Alba A Brandes, J Gregory Cairncross, Johan M Kros, Lynn S Ashby, Martin J B Taphoorn, Luis Souhami, Winand N M Din...> ;Journal of Clinical Oncology. 2022 Aug 10
22 citations
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, effic...
Priya U Kumthekar, Michael J Avram, Andrew B Lassman, Nancy U Lin, Eudocia Lee, Sean A Grimm, Margaret Schwartz, Kirsten L Bell Burdett, Rimas V Lukas, Karan Dixit, Is...> ;Neuro-Oncology. 2023 Mar 14
22 citations
EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors.
Roberta Rudà, David Capper, Adam D Waldman, Johan Pallud, Giuseppe Minniti, Thomas J Kaley, Eric Bouffet, Ghazaleh Tabatabai, Eleonora Aronica, Asgeir S Jakola, Stefan...> ;Neuro-Oncology. 2022 Dec 1
31 citations
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Andrew B Lassman, Stephanie L Pugh, Tony J C Wang, Kenneth Aldape, Hui K Gan, Matthias Preusser, Michael A Vogelbaum, Erik P Sulman, Minhee Won, Peixin Zhang, Golnaz M...> ;Neuro-Oncology. 2023 Feb 14
24 citations
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Moran, S. E., Andrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, Miguel J Gil-Gil, Vinay K Puduvalli, Jeffrey J Raizer, Filip Y F De Vos, Patrick Y ...> ;Clinical Cancer Research. 2022 Jun 1
6 citations
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.
Benjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, Caroline Chung, Howard Colman, Patricia E Cole, David Leung, Joshua E Allen, Manmeet S Ahluwalia, Jerrold...> ;Neuro-Oncology. 2022 Aug 1
211 citations
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.
Michael A Vogelbaum, Paul D Brown, Hans Messersmith, Priscilla K Brastianos, Stuart Burri, Dan Cahill, Ian F Dunn, Laurie E Gaspar, Na Tosha N Gatson, Vinai Gondi, Jus...> ;Journal of Clinical Oncology. 2022 Feb 10
51 citations
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Nimish A Mohile, Hans Messersmith, Na Tosha Gatson, Andreas F Hottinger, Andrew Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olso...> ;Journal of Clinical Oncology. 2022 Feb 1
Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study.
Marissa Barbaro, Craig D. Blinderman, Fabio M. Iwamoto, Teri N. Kreisl, Mary Welch, Yazmin Odia, Laura E. Donovan, Adela E. Joanta-Gomez, Katharine A. Evans, Andrew B....> ;Neurology. 2021 Nov 18
20 citations
A Phase 2 Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Andrew B. Lassman, Patrick Y. Wen, Martin J. van den Bent, Scott R. Plotkin, Annemiek M E Walenkamp, Adam L. Green, Kai Li, Christopher J. Walker, Hua Chang, Sharon Ta...> ;Clinical Cancer Research. 2021 Nov 2
5 citations
Diagnosis of leptomeningeal metastasis in women with breast cancer through identification of tumor cells in cerebrospinal fluid using the CNSide™ assay.
Margaux Wooster, Julia E. McGuinness, Kathleen Fenn, Veena M. Singh, Lauren Franks, Shing Lee, David Cieremans, Andrew B. Lassman, Dawn L. Hershman, Katherine D. Crew,...> ;Clinical Breast Cancer. 2021 Nov 1
7 citations
Report of National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from COVID-19 Experience.
Eudocia Q. Lee, Wendy Selig, Clair Meehan, Jeffrey A. Bacha, Amy Barone, Erik Bloomquist, Susan M. Chang, John de Groot, Evanthia Galanis, Islam Hassan, Chitkala Kalid...> ;Neuro-Oncology. 2021 Apr 2
2 citations
Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?
Andrew B. Lassman, Timothy F. Cloughesy> ;Neuro-Oncology. 2021 Mar 25
6 citations
Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
Hui K Gan, Sagun Parakh, Andrew B. Lassman, Aidan Seow, Eddie Lau, Sze Ting Lee, Malaka Ameratunga, Yuliya Perchyonok, Diana Cao, Ingrid Burvenich, Graeme O'Keefe, Ang...> ;Neuro-Oncology Advances. 2021 Jan 1
471 citations
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen, Michael Weller, Eudocia Q. Lee, Brian M. Alexander, Jill S. Barnholtz-Sloan, Floris P. Barthel, Tracy T. Batchelor, Ranjit S. Bindra, Susan M. Chang, E...> ;Neuro-Oncology. 2020 Aug 1
1 citations
Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
Aya Haggiagi, Andrew B. Lassman> ;Neuro-Oncology. 2020 Aug 17
23 citations
Current usage of tumor treating fields for glioblastoma.
Andrew B. Lassman, Adela Joanta-Gomez, Peter C. Pan, Wolfgang Wick> ;Neuro-Oncology Advances. 2020 Jan 1
Repeat Radiation in the Brain: Managing Patients With Locally Recurrent Glioma.
Daniel M. Trifiletti, Timothy D. Malouff, Susan L. McGovern, Shiao Pei Weathers, Tony J. C. Wang, Andrew B. Lassman, Daniel P. Cahill, Helen A. Shih, Paul D. Brown> ;Seminars in Radiation Oncology. 2020 Jul 1
42 citations
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer.
Rachna Malani, Martin Fleisher, Priya Kumthekar, Xuling Lin, Antonio Omuro, Morris D. Groves, Nan Lin, Michelle E. Melisko, Andrew B. Lassman, Suriya Jeyapalan, Andrew...> ;Journal of Neuro-Oncology. 2020 Jun 6
Join now to see all

Lectures

Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM).
2019 ASCO Annual Meeting - 6/1/2019
Efficacy and safety of selinexor in recurrent glioblastoma.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Brain Cancer: The Latest Advancements on Diagnostics, TreatmentOctober 25th, 2022
Conversation with Anil K. Rustgi, MD, on Visit by Jill Biden and Queen of SpainSeptember 21st, 2022
Promising Treatment for Deadly Brain CancerFebruary 4th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

New York-Presbyterian HospitalNew York, New York
NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York
Valley HospitalRidgewood, New Jersey

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Healthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment